NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
For more information regarding accessibility, please use the following form to contact us
* denotes a required field